[A clinical and experimental study of longatsef].
Data are reported of the results of clinical trials of the therapeutic efficacy of longaceph--a drug of the new generation of cephalosporins with a long period of half-decay--in acute pneumonia complicating influenza in 42 patients. The sensitivity of 120 microbial strains to longaceph was also studied. It was established that cephalosporin possesses a high efficacy in diseases caused by gram-positive and gram-negative microorganisms. A high degree of sensitivity to longaceph was observed in pneumococci biogenous and Streptococcus viridans, Staphylococcus aureus and epidermidis, klebsiellae and escherichiae. A new property of longaceph was found, namely, its capacity to stimulate the formation of endogenous interferon.
Frolov
A F
AF
Trinus
E K
EK
Rudenko
A A
AA
Diadiun
S T
ST
Antonenko
S V
SV
D000328:Adult; D001424:Bacterial Infections / Q000097:blood / Q000188:drug therapy / Q000382:microbiology; D002443:Ceftriaxone / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004247:DNA / Q000097:blood / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D007372:Interferons / Q000097:blood; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy / Q000382:microbiology
D002511:Cephalosporins; D003692:Delayed-Action Preparations; D002443:Ceftriaxone; D004247:DNA; D007372:Interferons
Kliniko-éksperimental'noe izuchenie longatsefa.